{"id":4294,"date":"2023-03-17T08:43:07","date_gmt":"2023-03-17T08:43:07","guid":{"rendered":"https:\/\/www.eurocytology.eu\/course\/4294-2\/"},"modified":"2023-04-24T08:42:00","modified_gmt":"2023-04-24T08:42:00","slug":"diagnosi-di-tumori-occulti-in-stadi-precoci","status":"publish","type":"course","link":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/","title":{"rendered":"Diagnosi di tumori occulti in stadi precoci"},"content":{"rendered":"<div data-object_id=\"4294\" class=\"cbxwpbkmarkwrap cbxwpbkmarkwrap_guest cbxwpbkmarkwrap_user_cat cbxwpbkmarkwrap-course \"><a  data-redirect-url=\"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294\/\"  data-display-label=\"1\" data-show-count=\"1\" data-bookmark-label=\"Bookmark\"  data-bookmarked-label=\"Bookmarked\"  data-loggedin=\"0\" data-type=\"course\" data-object_id=\"4294\" class=\"cbxwpbkmarktrig  cbxwpbkmarktrig-button-addto\" title=\"Bookmark This\" href=\"#\"><span class=\"cbxwpbkmarktrig-label\" >Bookmark (<i class=\"cbxwpbkmarktrig-count\">0<\/i>)<\/span><\/a> <div  data-type=\"course\" data-object_id=\"4294\" class=\"cbxwpbkmarkguestwrap\" id=\"cbxwpbkmarkguestwrap-4294\"><div class=\"cbxwpbkmarkguest-message\"><a href=\"#\" class=\"cbxwpbkmarkguesttrig_close\"><\/a><h3 class=\"cbxwpbookmark-title cbxwpbookmark-title-login\">Please login to bookmark<\/h3><form name=\"loginform\" id=\"loginform\" action=\"https:\/\/www.eurocytology.eu\/wp-login.php\" method=\"post\"><p class=\"login-username\">\n\t\t\t\t<label for=\"user_login\">Nome utente o indirizzo email<\/label>\n\t\t\t\t<input type=\"text\" name=\"log\" id=\"user_login\" autocomplete=\"username\" class=\"input\" value=\"\" size=\"20\" \/>\n\t\t\t<\/p><p class=\"login-password\">\n\t\t\t\t<label for=\"user_pass\">Password<\/label>\n\t\t\t\t<input type=\"password\" name=\"pwd\" id=\"user_pass\" autocomplete=\"current-password\" spellcheck=\"false\" class=\"input\" value=\"\" size=\"20\" \/>\n\t\t\t<\/p><p class=\"login-remember\"><label><input name=\"rememberme\" type=\"checkbox\" id=\"rememberme\" value=\"forever\" \/> Ricordami<\/label><\/p><p class=\"login-submit\">\n\t\t\t\t<input type=\"submit\" name=\"wp-submit\" id=\"wp-submit\" class=\"button button-primary\" value=\"Accedi\" \/>\n\t\t\t\t<input type=\"hidden\" name=\"redirect_to\" value=\"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294\/\" \/>\n\t\t\t<\/p><\/form><p class=\"cbxwpbookmark-guest-register\">No account yet? <a href=\"https:\/\/www.eurocytology.eu\/it\/register\/?redirect_to=https%3A%2F%2Fwww.eurocytology.eu%2Fit%2Fwp-json%2Fwp%2Fv2%2Fcourse%2F4294%2F\">Register<\/a><\/p><\/div><\/div><\/div><p>La diagnosi di tumori infiltranti occulti in donne asintomatiche pu\u00f2 aumentare l\u2019incidenza del tumore nei primi anni di screening organizzato.<\/p>\n<p>A Southampton, in una audit comprendente 382 tumori dal 1985 al 1996 eseguita&nbsp; in occasione dell\u2019introduzione di uno screening pi\u00f9 organizzato rispetto al precedente pi\u00f9 opportunistico e con uno scarso controllo di qualit\u00e0, evidenzi\u00f2 una crescita dei tumori diagnosticati con lo screening rispetto a quelli sintomatici, con un aumento dell\u2019incidenza totale (Figure 6.7).<\/p>\n<p>I tumori riscontrati allo screening sono pi\u00f9 facilmente allo stadio I: Andrae et al. (2008) hanno riportato che il 91% dei tumori diagnosticati allo screening si pu\u00f2 dividere equamente negli stadi IA e IB rispetto al 51% dei tumori sintomatici (12% IA, 39% IB). &nbsp;<\/p>\n<table border=\"3\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 500px;\">\n<tbody>\n<tr>\n<td>\n<h3>Tumori diagnosticati con lo screening<\/h3>\n<ul>\n<li>I tumori diagnosticati con lo screening possono aumentare l\u2019incidenza totale del tumore nelle prime fasi di uno screening organizzato.<\/li>\n<li>I tumori riscontrati allo screening sono di solito diagnosticati agli stadi IA o IB.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<figure><a data-toggle=\"modal\" href=\"#modal-container-2\"><img fetchpriority=\"high\" decoding=\"async\" alt=\"\" height=\"403\" src=\"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF\" width=\"493\" \/><\/a><figcaption>Figure 6.7. Trend da neoplasie sintomatiche a tumori diagnosticati con lo screening a Southampton (Figura 1 da Herbert et al. 2009)<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<p><strong>Riassumendo<\/strong>, i dati raccolti da programmi ben organizzati pubblicati pi\u00f9 di 25 anni fa e allo stesso modo per quelli pi\u00f9 recenti, dimostrano che bisogna considerare molteplici fattori quando si calcola l\u2019efficacia o l\u2019incidenza e la mortalit\u00e0.<\/p>\n<p>&nbsp;<\/p>\n<table border=\"3\" cellpadding=\"0\" cellspacing=\"0\" style=\"width:500px;\">\n<tbody>\n<tr>\n<td>\n<h3 style=\"margin-left: 17.85pt;\">Measurement of the effect of centrally organised screening depends on<\/h3>\n<ul>\n<li>Accuratezza nel registrare i tumori<\/li>\n<li>Effetti dello screening spontaneo portato avanti insieme a quello organizzato<\/li>\n<li>Fasce d\u2019et\u00e0 delle donne monitorate e intervalli di screening<\/li>\n<li>Compliance con le indicazioni<\/li>\n<li>Rischio di malattia nelle diverse fasce d\u2019et\u00e0<\/li>\n<li>Distinzione tra i tumori diagnosticati con lo screening e quelli sintomatici<\/li>\n<li>Controllo di qualit\u00e0 in tutti gli aspetti del programma.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<table border=\"3\" cellpadding=\"0\" cellspacing=\"0\" style=\"width:500px;\">\n<tbody>\n<tr>\n<td>\n<h3>Learning points del Capitolo 6<\/h3>\n<ol>\n<li>Uno screening organizzato della popolazione pu\u00f2 ridurre l\u2019incidenza del tumore cervicale e la mortalit\u00e0 dell\u201980%.<\/li>\n<li>I cambiamenti nell\u2019incidenza e nella mortalit\u00e0 del tumore possono essere mascherati dai cambiamenti nella prevalenza dell\u2019HPV nella popolazione.<\/li>\n<li>La stima dell\u2019effetto dello screening dipende da una accurata registrazione dei tumori.<\/li>\n<li>L\u2019apparente efficacia dello screening organizzato pu\u00f2 essere influenzata dallo screening spontaneo della stessa popolazione.<\/li>\n<li>L\u2019efficacia dello screening dipende dall\u2019aderenza alle raccomandazioni.<\/li>\n<li>L\u2019efficacia dello screening dipende dal range d\u2019et\u00e0 delle donne e dagli intervalli tra i test.<\/li>\n<li>Il controllo di qualit\u00e0 di tutti gli aspetti del programma \u00e8 essenziale per uno screening efficace.<\/li>\n<li>Le prime fasi di uno screening efficace potrebbero aumentare l\u2019incidenza attraverso la diagnosi di tumori infiltranti occulti in donne asintomatiche.<\/li>\n<\/ol>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<div data-object_id=\"4294\" class=\"cbxwpbkmarkwrap cbxwpbkmarkwrap_guest cbxwpbkmarkwrap_user_cat cbxwpbkmarkwrap-course \"><a  data-redirect-url=\"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294\/\"  data-display-label=\"1\" data-show-count=\"1\" data-bookmark-label=\"Bookmark\"  data-bookmarked-label=\"Bookmarked\"  data-loggedin=\"0\" data-type=\"course\" data-object_id=\"4294\" class=\"cbxwpbkmarktrig  cbxwpbkmarktrig-button-addto\" title=\"Bookmark This\" href=\"#\"><span class=\"cbxwpbkmarktrig-label\" >Bookmark (<i class=\"cbxwpbkmarktrig-count\">0<\/i>)<\/span><\/a> <div  data-type=\"course\" data-object_id=\"4294\" class=\"cbxwpbkmarkguestwrap\" id=\"cbxwpbkmarkguestwrap-4294\"><div class=\"cbxwpbkmarkguest-message\"><a href=\"#\" class=\"cbxwpbkmarkguesttrig_close\"><\/a><h3 class=\"cbxwpbookmark-title cbxwpbookmark-title-login\">Please login to bookmark<\/h3><form name=\"loginform\" id=\"loginform\" action=\"https:\/\/www.eurocytology.eu\/wp-login.php\" method=\"post\"><p class=\"login-username\">\n\t\t\t\t<label for=\"user_login\">Nome utente o indirizzo email<\/label>\n\t\t\t\t<input type=\"text\" name=\"log\" id=\"user_login\" autocomplete=\"username\" class=\"input\" value=\"\" size=\"20\" \/>\n\t\t\t<\/p><p class=\"login-password\">\n\t\t\t\t<label for=\"user_pass\">Password<\/label>\n\t\t\t\t<input type=\"password\" name=\"pwd\" id=\"user_pass\" autocomplete=\"current-password\" spellcheck=\"false\" class=\"input\" value=\"\" size=\"20\" \/>\n\t\t\t<\/p><p class=\"login-remember\"><label><input name=\"rememberme\" type=\"checkbox\" id=\"rememberme\" value=\"forever\" \/> Ricordami<\/label><\/p><p class=\"login-submit\">\n\t\t\t\t<input type=\"submit\" name=\"wp-submit\" id=\"wp-submit\" class=\"button button-primary\" value=\"Accedi\" \/>\n\t\t\t\t<input type=\"hidden\" name=\"redirect_to\" value=\"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294\/\" \/>\n\t\t\t<\/p><\/form><p class=\"cbxwpbookmark-guest-register\">No account yet? <a href=\"https:\/\/www.eurocytology.eu\/it\/register\/?redirect_to=https%3A%2F%2Fwww.eurocytology.eu%2Fit%2Fwp-json%2Fwp%2Fv2%2Fcourse%2F4294%2F\">Register<\/a><\/p><\/div><\/div><\/div><p>La diagnosi di tumori infiltranti occulti in donne asintomatiche pu\u00f2 aumentare l\u2019incidenza del tumore nei primi anni di screening organizzato. A Southampton, in una audit comprendente 382 tumori dal 1985 al 1996 eseguita&nbsp; in occasione dell\u2019introduzione di uno screening pi\u00f9 organizzato rispetto al precedente pi\u00f9 opportunistico e con uno scarso controllo di qualit\u00e0, evidenzi\u00f2 una [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":4286,"menu_order":0,"template":"","meta":[],"tags":[],"course_area":[97],"authors":[],"class_list":["post-4294","course","type-course","status-publish","hentry","course_area-cervice"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Diagnosi di tumori occulti in stadi precoci - Eurocytology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l\u0092effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diagnosi di tumori occulti in stadi precoci - Eurocytology\" \/>\n<meta property=\"og:description\" content=\"La diagnosi di tumori infiltranti occulti in donne asintomatiche pu\u00f2 aumentare l\u2019incidenza del tumore nei primi anni di screening organizzato. A Southampton, in una audit comprendente 382 tumori dal 1985 al 1996 eseguita&nbsp; in occasione dell\u2019introduzione di uno screening pi\u00f9 organizzato rispetto al precedente pi\u00f9 opportunistico e con uno scarso controllo di qualit\u00e0, evidenzi\u00f2 una [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l\u0092effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/\" \/>\n<meta property=\"og:site_name\" content=\"Eurocytology\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-24T08:42:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/\",\"url\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/\",\"name\":\"Diagnosi di tumori occulti in stadi precoci - Eurocytology\",\"isPartOf\":{\"@id\":\"https:\/\/www.eurocytology.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF\",\"datePublished\":\"2023-03-17T08:43:07+00:00\",\"dateModified\":\"2023-04-24T08:42:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#primaryimage\",\"url\":\"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF\",\"contentUrl\":\"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.eurocytology.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Courses\",\"item\":\"https:\/\/www.eurocytology.eu\/course\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Cervice\",\"item\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"6. L\u2019effetto dello screening su incidenza e mortalit\u00e0\",\"item\":\"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Diagnosi di tumori occulti in stadi precoci\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.eurocytology.eu\/#website\",\"url\":\"https:\/\/www.eurocytology.eu\/\",\"name\":\"Eurocytology\",\"description\":\"The Eurocytology project is supported by the Leonardo da Vinci program with the aim of increasing access to training in clinical cytology and of harmonising training in this important specialty of pathology throughout the EU.\",\"publisher\":{\"@id\":\"https:\/\/www.eurocytology.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.eurocytology.eu\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.eurocytology.eu\/#organization\",\"name\":\"Eurocytology\",\"url\":\"https:\/\/www.eurocytology.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.eurocytology.eu\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.eurocytology.eu\/wp-content\/uploads\/2023\/02\/logo_white.png\",\"contentUrl\":\"https:\/\/www.eurocytology.eu\/wp-content\/uploads\/2023\/02\/logo_white.png\",\"width\":250,\"height\":76,\"caption\":\"Eurocytology\"},\"image\":{\"@id\":\"https:\/\/www.eurocytology.eu\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diagnosi di tumori occulti in stadi precoci - Eurocytology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l\u0092effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/","og_locale":"it_IT","og_type":"article","og_title":"Diagnosi di tumori occulti in stadi precoci - Eurocytology","og_description":"La diagnosi di tumori infiltranti occulti in donne asintomatiche pu\u00f2 aumentare l\u2019incidenza del tumore nei primi anni di screening organizzato. A Southampton, in una audit comprendente 382 tumori dal 1985 al 1996 eseguita&nbsp; in occasione dell\u2019introduzione di uno screening pi\u00f9 organizzato rispetto al precedente pi\u00f9 opportunistico e con uno scarso controllo di qualit\u00e0, evidenzi\u00f2 una [&hellip;]","og_url":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l\u0092effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/","og_site_name":"Eurocytology","article_modified_time":"2023-04-24T08:42:00+00:00","og_image":[{"url":"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF"}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/","url":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/","name":"Diagnosi di tumori occulti in stadi precoci - Eurocytology","isPartOf":{"@id":"https:\/\/www.eurocytology.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#primaryimage"},"image":{"@id":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#primaryimage"},"thumbnailUrl":"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF","datePublished":"2023-03-17T08:43:07+00:00","dateModified":"2023-04-24T08:42:00+00:00","breadcrumb":{"@id":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#primaryimage","url":"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF","contentUrl":"http:\/\/lnx.eurocytology.eu\/sites\/default\/files\/styles\/max\/public\/images\/2225_1427306859.png?itok=QWk8VyVF"},{"@type":"BreadcrumbList","@id":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/diagnosi-di-tumori-occulti-in-stadi-precoci\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.eurocytology.eu\/"},{"@type":"ListItem","position":2,"name":"Courses","item":"https:\/\/www.eurocytology.eu\/course\/"},{"@type":"ListItem","position":3,"name":"Cervice","item":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/"},{"@type":"ListItem","position":4,"name":"6. L\u2019effetto dello screening su incidenza e mortalit\u00e0","item":"https:\/\/www.eurocytology.eu\/it\/course\/cervice-2\/6-l%c2%92effetto-dello-screening-su-incidenza-e-mortalita\/"},{"@type":"ListItem","position":5,"name":"Diagnosi di tumori occulti in stadi precoci"}]},{"@type":"WebSite","@id":"https:\/\/www.eurocytology.eu\/#website","url":"https:\/\/www.eurocytology.eu\/","name":"Eurocytology","description":"The Eurocytology project is supported by the Leonardo da Vinci program with the aim of increasing access to training in clinical cytology and of harmonising training in this important specialty of pathology throughout the EU.","publisher":{"@id":"https:\/\/www.eurocytology.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.eurocytology.eu\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.eurocytology.eu\/#organization","name":"Eurocytology","url":"https:\/\/www.eurocytology.eu\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.eurocytology.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.eurocytology.eu\/wp-content\/uploads\/2023\/02\/logo_white.png","contentUrl":"https:\/\/www.eurocytology.eu\/wp-content\/uploads\/2023\/02\/logo_white.png","width":250,"height":76,"caption":"Eurocytology"},"image":{"@id":"https:\/\/www.eurocytology.eu\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course"}],"about":[{"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/types\/course"}],"version-history":[{"count":3,"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294\/revisions"}],"predecessor-version":[{"id":4907,"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4294\/revisions\/4907"}],"up":[{"embeddable":true,"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course\/4286"}],"wp:attachment":[{"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/media?parent=4294"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/tags?post=4294"},{"taxonomy":"course_area","embeddable":true,"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/course_area?post=4294"},{"taxonomy":"authors","embeddable":true,"href":"https:\/\/www.eurocytology.eu\/it\/wp-json\/wp\/v2\/authors?post=4294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}